NRIX - CIK 0001549595
Nurix Therapeutics, Inc. (NRIX) reported revenue of $83.98M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $83.98M | +54.0% |
| FY 2024 | $54.55M | -29.1% |
| FY 2023 | $76.99M | +99.3% |
| FY 2022 | $38.63M | +29.8% |
| FY 2021 | $29.75M | +66.9% |
| FY 2020 | $17.82M | -42.7% |
| FY 2019 | $31.11M | - |
Nurix Therapeutics, Inc. (NRIX) reported revenue of $83.98M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2019 and fiscal 2025, Nurix Therapeutics, Inc.'s revenue grew from $31.11M to $83.98M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.